A study testing whether a new weekly shot from The University of Texas Health Science Center at San Antonio, tirzepatide, can help with weight.
- Who can join
- Adults 50+, have obesity, BMI 30+.
- What you take
- tirzepatide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The study runs about 14 months.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Obesity Prevention. Also studied in: Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss.
Full scientific study title: Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults.
Who can join
Adults 50+, have obesity, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Men and postmenopausal women aged 50 years or older.
- Body Mass Index (BMI) >=30 kg/m².
- Untreated HbA1c <6.5% at baseline.
- Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.
- Able to provide informed consent and participate in all study assessments.
Key exclusion criteria
- Active diagnosis of type 2 diabetes mellitus (T2DM), defined by active use of glucose-lowering medications or hemoglobin A1c >= 6.5%.
- Body Mass Index (BMI) >= 40 kg/m².
- Moderate to severe gastroesophageal reflux disease based on patient history.
- Inability to comply with the treatment protocol or to understand the consent form.
- Chronic Kidney Disease (CKD) Stage 4.
Where this study is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Texas1 site
- University of Texas Health Science Center at San AntonioSan Antonio, TexasShreya Raoraos4@uthscsa.edu
Timeline
Started enrolling: 2026-04-01. Expected completion: 2027-06-01. Last updated on ClinicalTrials.gov: 2026-04-15.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
